Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria:

* non-hematological advanced solid tumor malignancy or lymphoma where no curative therapy exists in which monotherapy with gemcitabine or docetaxel or bevacizumab or erlotinib or cisplatin, or 5-flurouracil or sunitinib would otherwise be warranted.
* measurable disease based on radiographic evaluation or elevated tumor markers.
* ECOG - 0 or 1 (KPS \>70).
* Life expectancy \> 3 months.

Exclusion Criteria:

* chemotherapy within 21 days or radiotherapy within 4 weeks prior to entering the study
* known active brain metastases or leptomeningeal carcinomatosis.
* history of a myocardial infarction within the prior 6 months or, hospitalizations for congestive heart failure within the prior 6 months, or active treatment for uncontrolled cardiac arrhythmias
* clinically significant gastrointestinal tract hemorrhage, requiring transfusion therapy, within the prior 3 months.